The present invention discloses a method for separating flavonoid substances in Camellia nitidissima Chi based on a magnetic nanoparticles-PAMAM nano composites, which comprises the following steps: preparing PAMAM dendrimer, then using the PAMAM dendrimer to prepare the magnetic nanoparticles-PAMAM nano composites, then adding the obtained magnetic nanoparticles-PAMAM nano composites in a Camellia nitidissima Chi extract, extracting and performing magnetic separation on the flavonoid substances in Camellia nitidissima Chi under ultrasound or microwave condition. According to the present invention, flavonoid substances with faintly acid characteristics are extracted and adsorbed in a plant concentrate such as Camellia nitidissima Chi or Hedyotis diffusa etc. based on the magnetic nanoparticles-PAMAM nano composites, in a successive step, high efficiency separation of the flavonoid substances can be realized by the technologies such as magnetic separation and microwave-assisted extraction.

The present invention discloses a method for separating flavonoid substances in Camellia nitidissima Chi based on a magnetic nanoparticles-PAMAM nano composites, which comprises the following steps: preparing PAMAM dendrimer, then using the PAMAM dendrimer to prepare the magnetic nanoparticles-PAMAM nano composites, then adding the obtained magnetic nanoparticles-PAMAM nano composites in a Camellia nitidissima Chi extract, extracting and performing magnetic separation on the flavonoid substances in Camellia nitidissima Chi under ultrasound or microwave condition. According to the present invention, flavonoid substances with faintly acid characteristics are extracted and adsorbed in a plant concentrate such as Camellia nitidissima Chi or Hedyotis diffusa etc. based on the magnetic nanoparticles-PAMAM nano composites, in a successive step, high efficiency separation of the flavonoid substances can be realized by the technologies such as magnetic separation and microwave-assisted extraction.

In certain embodiments APP-specific BACE inhibitors (ASBIs) are provided as well as uses thereof. In certain embodiments methods of preventing delaying the onset of a pre-Alzheimer's condition and/or cognitive dysfunction, and/or ameliorating one or more symptoms of a pre-Alzheimer's condition and/or cognitive dysfunction, or preventing or delaying the progression of a pre-Alzheimer's condition or cognitive dysfunction to Alzheimer's disease are provided where the method involves administering to a subject in need thereof an APP specific BACE inhibitor (ASBI) in an amount sufficient to prevent or delay the onset of a pre-Alzheimer's cognitive dysfunction, and/or to ameliorate one or more symptoms of a pre-Alzheimer's cognitive dysfunction, and/or to prevent or delay the progression of a pre-Alzheimer's cognitive dysfunction to Alzheimer's disease. In certain embodiments the ASBI is a flavonoid (e.g. galangin) or flavonoid progrug (e.g., galangin prodrug).

In certain embodiments APP-specific BACE inhibitors (ASBIs) are provided as well as uses thereof. In certain embodiments methods of preventing delaying the onset of a pre-Alzheimer's condition and/or cognitive dysfunction, and/or ameliorating one or more symptoms of a pre-Alzheimer's condition and/or cognitive dysfunction, or preventing or delaying the progression of a pre-Alzheimer's condition or cognitive dysfunction to Alzheimer's disease are provided where the method involves administering to a subject in need thereof an APP specific BACE inhibitor (ASBI) in an amount sufficient to prevent or delay the onset of a pre-Alzheimer's cognitive dysfunction, and/or to ameliorate one or more symptoms of a pre-Alzheimer's cognitive dysfunction, and/or to prevent or delay the progression of a pre-Alzheimer's cognitive dysfunction to Alzheimer's disease. In certain embodiments the ASBI is a flavonoid (e.g. galangin) or flavonoid progrug (e.g., galangin prodrug).

The present invention provides novel compounds having the general formula (I) wherein R.sup.1 to R.sup.6, and m are as described herein, compositions including the compounds and methods of using the compounds. ##STR00001##

The present invention provides novel compounds having the general formula (I) wherein R.sup.1 to R.sup.6, and m are as described herein, compositions including the compounds and methods of using the compounds. ##STR00001##

Described herein are methods of treating neuron inflammation conditions, for example, Alzheimer's disease, Parkinson's disease, Huntington's disease, ischemic stroke, and prion disease, comprising administering a therapeutically effective amount of cromolyn or a cromolyn derivative compound.

The present invention relates to a combination comprising cromoglicic acid or derivatives thereof and to dermatological compositions comprising said composition. The invention also relates to the use of said combination or composition for the treatment of dermatitis.

Novel cromolyn analogs useful as imaging agents for detecting atherosclerotic plaques and for treating atherosclerosis and Alzheimer's Disease, and methods of making the cromolyn analogs, are disclosed. The cromolyn analogs have the general formula:

##STR00001##

wherein: X is OH, C.sub.1-C.sub.6 alkoxyl; Y and Z are independently selected form a C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkoxyl, halogen, un-substiuted or C.sub.1-C.sub.6 substituted amine, .sup.18F, .sup.19F, or H; and n is 1, 2, or 3; and wherein for structure (I), if n are both 1 and Y and Z are both H and X is OH.

Novel cromolyn analogs useful as imaging agents for detecting atherosclerotic plaques and for treating atherosclerosis and Alzheimer's Disease, and methods of making the cromolyn analogs, are disclosed. The cromolyn analogs have the general formula:

##STR00001##

wherein: X is OH, C.sub.1-C.sub.6 alkoxyl; Y and Z are independently selected form a C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkoxyl, halogen, un-substiuted or C.sub.1-C.sub.6 substituted amine, .sup.18F, .sup.19F, or H; and n is 1, 2, or 3; and wherein for structure (I), if n are both 1 and Y and Z are both H and X is OH.